Sobi spotlights olezarsen pancreatitis data at EAS 2026: full analysis

Sobi is using EAS 2026 to sharpen the clinical story around olezarsen in severe hypertriglyceridemia. In a new pooled subgroup analysis from the Phase 3 CORE and CORE2 trials, the company said Tryngolza reduced triglycerides by 66% at six months and lowered the relative risk of acute pancreatitis by 85% in adults whose baseline triglycerides were at least 880 mg/dL, the threshold aligned with European Atherosclerosis Society guidance for severe hypertriglyceridemia. The results were presented May 26, 2026, as a late-breaking abstract in Athens. (sobi.com)

The update builds on data that have been in view since late 2025. CORE and CORE2 are global, randomized, double-blind, placebo-controlled Phase 3 studies conducted with the TIMI Study Group, enrolling 617 and 446 patients, respectively. Results from those trials were first highlighted at the American Heart Association Scientific Sessions in November 2025 and were later published in The New England Journal of Medicine in the January 29, 2026, issue, where investigators reported that olezarsen significantly reduced triglyceride levels and was associated with fewer episodes of acute pancreatitis than placebo. (prnewswire.com)

What’s changed now is the framing. Rather than emphasizing the overall severe hypertriglyceridemia population, Sobi is spotlighting the subgroup at the highest pancreatitis risk, patients starting at 880 mg/dL or above. According to the company, the pooled EAS analysis included 455 such patients and showed both a large triglyceride reduction and a statistically significant drop in pancreatitis events. That matters because severe hypertriglyceridemia has long been difficult to manage with standard lipid-lowering therapy alone, and pancreatitis prevention is often the core clinical goal in the sickest patients. (sobi.com)

Independent commentary around the earlier publication has pointed in the same direction. The New England Journal of Medicine editorial accompanying the January paper described management of severe hypertriglyceridemia for preventing complications such as hypertriglyceridemia-induced acute pancreatitis as historically challenging. Coverage in GI and Hepatology News similarly framed olezarsen as a potential new option for high-risk patients, noting the drug’s monthly dosing and its mechanism as an antisense oligonucleotide targeting apoC-III messenger RNA. (nejm.org)

For veterinary professionals, the direct clinical relevance is limited because this is a human lipid disorder therapy, not a veterinary product. Still, the development is worth watching as a marker of where translational medicine is heading. Drug programs are increasingly expected to show that they change hard outcomes, not just lab values, and Sobi’s messaging underscores that shift. It’s also a reminder that pancreatitis risk remains a powerful clinical and commercial anchor when companies position therapies for metabolically complex patients. In a veterinary setting, where hyperlipidemia and pancreatitis can also intersect, the broader lesson is about endpoint selection, risk stratification, and how sponsors build the case for adoption with specialists, regulators, and pet parents alike. (nejm.org)

The regulatory backdrop makes the EAS presentation more than a routine congress update. In March 2026, the EMA validated an indication extension application for olezarsen in adults with severe hypertriglyceridemia at or above 880 mg/dL, and in February 2026 Ionis said the FDA accepted a supplemental NDA for priority review, setting a June 30, 2026, target action date. That means this conference presentation lands during an active decision window, when companies often work to reinforce the clinical narrative for prescribers, payers, and investors. (prnewswire.com)

Why it matters: The bigger takeaway isn’t just that olezarsen lowers triglycerides. It’s that Sobi is trying to establish pancreatitis prevention as the headline benefit in the highest-risk subgroup, which could shape how the therapy is positioned against other apoC-III-targeting approaches and how future guidelines discuss treatment thresholds. If regulators and clinicians accept that framing, it could strengthen the case for earlier identification and more aggressive treatment of patients with very high triglyceride burdens. (sobi.com)

What to watch: The next milestones are the June 30, 2026, FDA decision, progress on the EMA indication extension, and whether additional real-world or longer-term data confirm that the pancreatitis benefit is durable beyond the six-month analysis window. (businesswire.com)